Hyperammonemia

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Liminal BioSciences
1 program
1
FezageprasPhase 11 trial
Active Trials
NCT05349435TerminatedEst. Jun 2022
Recordati
RecordatiFrance - Saint-Victor
1 program
Carglumic AcidN/A1 trial
Active Trials
NCT05040178Recruiting20Est. Jun 2032

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Liminal BioSciencesFezagepras
RecordatiCarglumic Acid

Clinical Trials (2)

Total enrollment: 20 patients across 2 trials

A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate

Start: May 2022Est. completion: Jun 2022
Phase 1Terminated
NCT05040178RecordatiCarglumic Acid

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

Start: Jun 2022Est. completion: Jun 203220 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 20 patients
2 companies competing in this space